MonumenTAL: Key Efficacy Outcomes

EP: 1.John’s Journey with R/R MM

Now Viewing

EP: 2.MonumenTAL: Key Efficacy Outcomes

EP: 3.Implications of Talquetamab on the Current Treatment Landscape for R/R MM

EP: 4.Bispecifics in R/R MM: Selecting the Best Bispecific and Optimal Sequencing Strategies

EP: 5.Eva’s Treatment Journey With R/R MM

EP: 6.MagnestisMM: Key Efficacy Data and its Clinical Implications

EP: 7.Elranatamab: Real-World Experience and Sequencing

EP: 8.Future of R/R MM: Emerging Agents

Video content above is prompted by the following:

• What characteristics make this patient particularly suitable for treatment with a bispecific antibody?
• Can you summarize the clinical evidence supporting talquetamab use in relapsed/refractory multiple myeloma (R/R MM)?
  • Could you highlight the primary efficacy outcomes from the monumenTAL trials?